RADIOPHARM THERANOSTICS LTD

RADX represents the common stock of a publicly traded company focused on developing radiopharmaceuticals and related diagnostic imaging technologies. The ticker is listed on a major U.S. exchange, and the company operates in the healthcare sector, specifically within the biotechnology and life sciences industry. For the most current corporate details, including recent developments and filings, refer to the RADX company profile on this page.

The current price of RADX stock fluctuates during market hours and is displayed at the top of this page. For the latest quote, including bid/ask spreads and volume, check the real-time data provided here. Since prices change continuously, any figure quoted in text would quickly become outdated; always rely on the live feed for accurate, up-to-date pricing information.

Recent performance for RADX can be assessed by looking at its price changes over the past days, weeks, or months, which are shown in the performance section of this page. The stock may have moved in response to company announcements, sector trends, or broader market conditions. For a detailed view, review the interactive chart and historical return figures provided above.

Useful valuation metrics for RADX include the price-to-earnings (P/E) ratio, price-to-sales (P/S), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA). Because many biotechnology companies have volatile or negative earnings, price-to-sales and cash flow-based multiples may be more informative. The relevant ratios for RADX are displayed in the valuation section of this page.

RADX may be available for trading in pre-market and after-hours sessions, depending on your broker and the exchange. These extended hours typically have lower liquidity and wider spreads than regular trading. To see if extended-hours trading is offered for RADX and to view any quotes, check the trading information section on this page.

Investing in RADX carries risks common to biotechnology and radiopharmaceutical companies, including clinical trial failures, regulatory delays, and heavy reliance on successful product development. Other risks include competition, intellectual property challenges, and the need for ongoing capital. Additionally, RADX may be subject to sector-specific volatility and broader market fluctuations. Review the risk factors in the company’s SEC filings and the risk summary on this page.